التفاصيل البيبلوغرافية
| العنوان: |
CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. |
| المؤلفون: |
Harbeck, Nadia, Bartlett, Meaghan, Spurden, Dean, Hooper, Becky, Zhan, Lin, Rosta, Emily, Cameron, Chris, Mitra, Debanjali, Zhou, Anna |
| المصدر: |
Future Oncology; Jun2021, Vol. 17 Issue 16, p2107-2122, 17p |
| مصطلحات موضوعية: |
PROTEIN metabolism, THERAPEUTIC use of antineoplastic agents, SYSTEMATIC reviews, CELL receptors, METASTASIS, TREATMENT effectiveness, TUMOR classification, TRANSFERASES, RESEARCH funding, BREAST tumors |
| مستخلص: |
Background: This review aims to qualitatively summarize the published real-world evidence (RWE) for CDK4/6 inhibitors (CDK4/6i) approved for treating HR+, HER2-negative advanced/metastatic breast cancer (HR+/HER2- a/mBC). Materials & methods: A systematic literature review was conducted to identify RWE studies of CDK4/6i in HR+/HER2- a/mBC published from 2015 to 2019. Results: This review identified 114 studies, of which 85 were only presented at scientific conferences. Most RWE studies investigated palbociclib and demonstrated improved outcomes. There are limited long-term and comparative data between CDK4/6i and endocrine monotherapy, and within the CDK4/6i class. Conclusion: Available RWE suggests that CDK4/6i are associated with improved outcomes in HR+/HER2- a/mBC, although additional studies with longer follow-up periods are needed. [ABSTRACT FROM AUTHOR] |
|
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
